Izidore S. Lossos

27.2k total citations · 2 hit papers
353 papers, 10.8k citations indexed

About

Izidore S. Lossos is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Izidore S. Lossos has authored 353 papers receiving a total of 10.8k indexed citations (citations by other indexed papers that have themselves been cited), including 255 papers in Pathology and Forensic Medicine, 135 papers in Oncology and 92 papers in Genetics. Recurrent topics in Izidore S. Lossos's work include Lymphoma Diagnosis and Treatment (252 papers), Chronic Lymphocytic Leukemia Research (82 papers) and Viral-associated cancers and disorders (61 papers). Izidore S. Lossos is often cited by papers focused on Lymphoma Diagnosis and Treatment (252 papers), Chronic Lymphocytic Leukemia Research (82 papers) and Viral-associated cancers and disorders (61 papers). Izidore S. Lossos collaborates with scholars based in United States, Israel and Spain. Izidore S. Lossos's co-authors include Ronald Levy, Ash A. Alizadeh, Yasodha Natkunam, Randy D. Gascoyne, David Botstein, Rob Tibshirani, Mark A. Wechser, Robert Tibshirani, Debra K. Czerwinski and Raquel Malumbres and has published in prestigious journals such as New England Journal of Medicine, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Izidore S. Lossos

334 papers receiving 10.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma

2010 845 citations Raquel Malumbres, Javier Briones et al. profile →
Prediction of Survival in Diffuse Large-B-Cell Lymphoma Based on the Expression of Six Genes

2004 708 citations Izidore S. Lossos, Rob Tibshirani et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Izidore S. Lossos United States	53	5.8k	4.3k	2.9k	2.8k	2.5k	353	10.8k
Eric D. Hsi United States	62	6.0k 1.0×	4.7k 1.1×	3.2k 1.1×	2.6k 1.0×	3.5k 1.4×	405	12.2k
Miguel Á. Piris Spain	66	8.5k 1.5×	6.3k 1.5×	3.6k 1.2×	2.8k 1.0×	3.9k 1.5×	328	14.2k
Daphne de Jong Netherlands	54	5.8k 1.0×	4.4k 1.0×	1.9k 0.6×	1.7k 0.6×	2.0k 0.8×	214	10.3k
Andreas Chott Austria	61	6.4k 1.1×	3.8k 0.9×	1.9k 0.6×	2.8k 1.0×	2.2k 0.9×	233	11.3k
German Ott Germany	64	8.7k 1.5×	6.2k 1.4×	2.7k 0.9×	2.0k 0.7×	4.0k 1.6×	336	12.9k
Falko Fend Germany	55	3.7k 0.6×	4.7k 1.1×	3.1k 1.1×	1.5k 0.6×	1.7k 0.7×	413	11.1k
Yasodha Natkunam United States	50	4.5k 0.8×	4.4k 1.0×	2.3k 0.8×	2.1k 0.8×	1.4k 0.6×	238	8.8k
Ken H. Young United States	52	4.2k 0.7×	4.4k 1.0×	2.8k 1.0×	2.0k 0.7×	1.9k 0.7×	242	9.3k
Hans Konrad Müller‐Hermelink Germany	58	7.5k 1.3×	4.9k 1.1×	2.0k 0.7×	2.9k 1.0×	3.1k 1.2×	194	13.6k
Lorenz Trümper Germany	42	3.9k 0.7×	3.3k 0.8×	1.9k 0.7×	1.6k 0.6×	2.1k 0.8×	203	7.5k

Countries citing papers authored by Izidore S. Lossos

Since Specialization

Citations

This map shows the geographic impact of Izidore S. Lossos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Izidore S. Lossos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Izidore S. Lossos more than expected).

Fields of papers citing papers by Izidore S. Lossos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Izidore S. Lossos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Izidore S. Lossos. The network helps show where Izidore S. Lossos may publish in the future.

Co-authorship network of co-authors of Izidore S. Lossos

This figure shows the co-authorship network connecting the top 25 collaborators of Izidore S. Lossos. A scholar is included among the top collaborators of Izidore S. Lossos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Izidore S. Lossos. Izidore S. Lossos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Strati, Paolo, Richy Agajanian, Izidore S. Lossos, et al.. (2024). Acalabrutinib in combination with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma: Results of the phase 1b open‐label study ( ACE ‐ LY ‐003). British Journal of Haematology. 206(3). 887–898. 2 indexed citations

Assouline, Sarit, Lihua E. Budde, Julio C. Chávez, et al.. (2024). Mosunetuzumab with polatuzumab vedotin: Subgroup analyses in patients (pts) with primary refractory or early relapsed large B-cell lymphoma (LBCL).. Journal of Clinical Oncology. 42(16_suppl). 7021–7021.

Alderuccio, Juan Pablo, Alvaro J. Alencar, Jonathan H. Schatz, et al.. (2024). Loncastuximab Tesirine with Rituximab Induces Robust and Durable Complete Metabolic Responses in High-Risk Relapsed/Refractory Follicular Lymphoma. Blood. 144(Supplement 1). 337–337. 2 indexed citations

Friedberg, Jonathan W., Michael T. Brady, Myla Strawderman, et al.. (2024). Vitamin D in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy (ILyAD): a randomized, phase 3 clinical trial. EClinicalMedicine. 78. 102959–102959. 3 indexed citations

Alderuccio, Juan Pablo, et al.. (2024). Transformation of marginal zone lymphoma to Hodgkin lymphoma. Blood Advances. 8(17). 4559–4562. 1 indexed citations

Link, Brian K., Matthew J. Maurer, Melissa C. Larson, et al.. (2024). Transformation in marginal zone lymphoma: results from a prospective cohort and a meta-analysis of the literature. Blood Advances. 8(23). 5939–5948. 2 indexed citations

Alderuccio, Juan Pablo & Izidore S. Lossos. (2021). NOTCH signaling in the pathogenesis of splenic marginal zone lymphoma—opportunities for therapy. Leukemia & lymphoma. 63(2). 279–290. 5 indexed citations

Alderuccio, Juan Pablo, Wei Zhao, Amrita Desai, et al.. (2019). Short survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentation. American Journal of Hematology. 94(5). 585–596. 26 indexed citations

Younes, Anas, John M. Burke, Bruce D. Cheson, et al.. (2019). Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analysis of a Phase I/II Study. Blood. 134(Supplement_1). 2874–2874. 20 indexed citations

10.

Qu, Changju, Kranthi Kunkalla, John K. Frederiksen, et al.. (2018). Smoothened stabilizes and protects TRAF6 from degradation: A novel non-canonical role of smoothened with implications in lymphoma biology. Cancer Letters. 436. 149–158. 8 indexed citations

11.

Tan, Yaohong, Alvaro J. Alencar, Joseph D. Rosenblatt, et al.. (2018). Splenic B-Cell Lymphomas with Diffuse Cyclin D1 Protein Expression and Increased Prolymphocytic Cells: A Previously Unrecognized Diagnostic Pitfall. SHILAP Revista de lepidopterología. 2018. 1–9. 2 indexed citations

12.

Friedberg, Jonathan W., Daruka Mahadevan, Daniel O. Persky, et al.. (2013). Phase II Study of Alisertib, a Selective Aurora A Kinase Inhibitor, in Relapsed and Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphomas. Journal of Clinical Oncology. 32(1). 44–50. 161 indexed citations

13.

Matasar, Matthew J., Myron S. Czuczman, Maria Alma Rodriguez, et al.. (2013). Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma. Blood. 122(4). 499–506. 45 indexed citations

14.

Alencar, Alvaro J., Raquel Malumbres, Ranjana H. Advani, et al.. (2011). MicroRNAs Are Independent Predictors of Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP. Clinical Cancer Research. 17(12). 4125–4135. 113 indexed citations

15.

Sarosiek, Kristopher A., Raquel Malumbres, Hovav Nechushtan, et al.. (2009). Novel IL-21 signaling pathway up-regulates c-Myc and induces apoptosis of diffuse large B-cell lymphomas. Blood. 115(3). 570–580. 66 indexed citations

16.

Sarosiek, Kristopher A., Hovav Nechushtan, Xiaoqing Lu, Joseph D. Rosenblatt, & Izidore S. Lossos. (2009). Interleukin‐4 distinctively modifies responses of germinal centre‐like and activated B‐cell‐like diffuse large B‐cell lymphomas to immuno‐chemotherapy. British Journal of Haematology. 147(3). 308–318. 10 indexed citations

17.

Mann, Koren K., Barbara Wallner, Izidore S. Lossos, & Wilson H. Miller. (2009). Darinaparsin: a novel organic arsenical with promising anticancer activity. Expert Opinion on Investigational Drugs. 18(11). 1727–1734. 62 indexed citations

18.

Wiernik, Peter H., Izidore S. Lossos, Joseph M. Tuscano, et al.. (2008). Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma. Journal of Clinical Oncology. 26(30). 4952–4957. 300 indexed citations

19.

Malumbres, Raquel, Jun Chen, Rob Tibshirani, et al.. (2008). Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Blood. 111(12). 5509–5514. 73 indexed citations

20.

Raanani, Pia, Ofer Shpilberg, Shmuel Gillis, et al.. (1999). Salvage therapy of refractory and relapsed acute leukemia with high dose mitoxantrone and high dose cytarabine. Leukemia Research. 23(8). 695–700. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact